Related Experiment Video

Updated: Jun 8, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Long-term cardiovascular risk following platinum-based chemotherapy for germ cell tumors

Clary Evans, Michael Williams, Danish Mazhar

    Future Oncology (London, England)
    |October 6, 2010
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
    04:48

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

    Published on: January 7, 2015

    Related Experiment Videos

    Last Updated: Jun 8, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
    04:48

    Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

    Published on: January 7, 2015

    Related Concept Videos

    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    VA-ECMO Weaning in Low-Flow Low-Gradient Aortic Stenosis Post STEMI and ECPR.

    JACC. Case reports·2026

    Outcomes of Coronary Artery Bypass Graft Surgery in Octogenarians: Results From the Australian Cardiac Surgery Database.

    Heart, lung & circulation·2026

    Innate-immune crosstalk orchestrates T cell-mediated rejection in kidney transplants.

    Frontiers in immunology·2026

    Reining in Unbridled AI Enthusiasm: Protecting the Integrity of Rehabilitation Science and Clinical Care.

    Archives of physical medicine and rehabilitation·2026

    Through their eyes': A qualitative study on the impact of virtual reality on parents' understanding of visual impairment.

    Eye (London, England)·2026

    Evaluating the Use of Google Street View to Visually Verify the Locations of Cannabis Retailers in the United States Extracted from Websites, 2015-2018.

    Applied spatial analysis and policy·2026

    Persistence and adherence to tepotinib in patients with metastatic non-small cell lung cancer: a real-world evidence study including dose reductions.

    Future oncology (London, England)·2026

    DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS <50% NSCLC.

    Future oncology (London, England)·2026

    The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?

    Future oncology (London, England)·2026

    Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.

    Future oncology (London, England)·2026

    PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.

    Future oncology (London, England)·2026

    Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

    Future oncology (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us